Cryptococcus neoformans: Paradigm for the role of antibody immunity against fungi?

Zentralblatt fur Bakteriologie

Volumn 284, Issue 4, 1996, Pages 475-495

  Pirofski, Liise Anne ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030221601     PISSN: 09348840     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0934-8840(96)80001-6     Document Type: Article

References (135)

1. Abrahams, I.: Further studies on acquired resistance to murine cryptococcosis: enhancing effect of Bordetella pertusis. J. Immunol. 96 (1966) 525-529
2. Adderson, E. E., P. G. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham, R. A. Insel, and W. L. Carroll: Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J. Clin. Invest. 91 (1993) 2734-2743
3. Alspaugh, J. A. and D. L. Granger: Inhibition of Cryptococcus neoformans replication by nitrogen oxide supports the role of these molecules as effectors of macrophage-mediated cystostasis. Infect. Immun. 59 (1991) 2291-2296
4. Ammann, A. J., G. Schiffman, D. Abrams, P. Volberding, J. Ziegler, and M. Conant: B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA251 (1984) 1447-1449
5. Apicella, M. A.: Neisseria meningitidis. In: Principles and practice of infectious diseases, edited by Mandell, G. L., Bennett, J. E. and Dolin, R. New York: Churchill Livingstone, 1995, p. 1896-1909
6. Baker, P. J.: Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect. Immun. 58 (1990) 3465-3468
7. Benham, R. W.: Cryptococci-Their identification by morphology and by serology. J. Infect. Dis. 57 (1935) 255-274
8. Bennett, J. E. and H. F. Hasenclever: Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection. J. Immunol. 94 (1965) 916-920
9. Briles, D. E., J. L. Claffin, K. Schroer, and C. Forman: Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294 (1981) 88-89
10. Bulmer, G. S., M. D. Sans, and C. M. Gunn: Cryptococcus neoformons. I. Nonencapsulated mutants. J. Bacteriol. 94 (1967) 1475-1479
11. Carson, P. J., R. L. Schut, M. L. Simpson, J. O'Brien and E. N. Janoff: Antibody class and subclass reponses to pneumococcal polysaccharides following immunization of human immunodeficiency virus infected patients. J. Infect.Dis. 172 (1995) 340-356
12. Casadevall, A.: Antibody immunity and invasive fungal infections. Infect. Immun. 63 (1995) 4211-4218
13. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T. R. Kozel, and L. Pirofski: Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62 (1994) 3864-3872
14. Casadevall, A., J. Dobroszycki, C. Small, and L. Pirofski: Hemophilus influenza type b bacteremia in patients with AIDS and at risk for AIDS. Am. J. Med. 92 (1992) 587-590
15. Casadevall, A., J. Mukherjee, S. J. N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff: Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65 (1992) 1086-1093
16. L usage in polysaccharide binding antibodies. J. Exp. Med. 174 (1991) 151-160
17. Casadevall, A. and M. D. Scharff: "Serum Therapy" revisited: Animal models of infection and the development of passive antibody therapy. Antimicrob. Agents Chemotherap. 62 (1994) 1507-1512
18. Cherniak, R. and J. B. Sundstrom: Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62 (1994) 1507-1512
19. Chuck, S. L. and M. A. Sande: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. New Engl. J. Med. 321 (1989) 794-799
20. Cleare, W., S. Mukherjee, E. D. Spitzer, and A. Casadevall: Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies. Clin. Diagn. Lab. Immunol. 1 (1994) 737-740
21. Currie, B. P. and A. Casadevall: Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19 (1994) 1029-1033
22. DeShaw, M. and L.-A. Pirofski: Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV + and HIV-individuals. Clin. Exp. Immunol. 99 (1995) 425-432
23. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett: Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59 (1991) 3700-3707
24. Diamond, R. D.: Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature 247 (1974) 870-874
25. Diamond, R. D. and A. C. Allison: Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect. Immun. 14 (1976) 716-720
26. Diamond, R. D. and J. E. Bennett: Prognostic factors in cryptococcal meningitis. Ann. Intern. Med. 80 (1974) 176-181
27. Diamond, R. D., J. E. May, M. C. Kane, M. M. Frank, and J. E. Bennett: The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112 (1974) 2260-2270
28. Dong, Z. M. and J. W. Murphy: Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun. 63 (1995) 2632-2644
29. Dromer, F., P. Aucouturier, J.-P. Clauvel, G. Saimot, and P. Yeni: Cryptocoecus neoformans antibody levels in patients with AIDS. Scan. J. Infect. Dis. 20 (1988) 283-285
30. Dromer, E and J. Charreire: Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcis and mechanisms of action. J. Infect. Dis. 163 (1991) 1114-1120
31. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni: Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55 (1987) 749-752
32. Dromer, F., C. Perrone, J. Barge, J. L. Vilde, and P. Yeni: Role of IgG and complement component C5 in the inital course of experimental cryptococcosis. Clin. Exp. Immunol. 78 (1989) 412-417
33. Dromer, F., P. Yeni, and J. Charreire: Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics 28 (1988) 417-424
34. Drouhet, E. and G. Segretain: Inhibition de la migration leucocytaire in vitro par un polyside capsulaire de Torulopsis (Cryptocoecus) neoformans. Ann. Inst. Pasteur 81 (1951) 674
35. Eng, R. H. K., E. Bishburg, S. M. Smith, H. Geller, and R. Kapila: Bacteremia and Fungemia in patients with the acquired immune deficiency syndrome. Am. J. Clin. Pathol. 86 (1986) 105-107
36. Feldmesser, M., J. Murkherjee, and A. Casadevall: Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptocoecus neoformans infections and in vitro. J. Antimicrob. Chemother. (in press) (1995)
37. French, D. L., R. Laskov, and M. D. Scharff: The role of somatic hypermutation in the generation of antibody diversity. Science 244 (1989) 1152-1157
38. Gadebusch, H. H.: Passive immunization against Cryptocoecus neoformans. Proc. Soc. Exp. Biol. Med. 98 (1958) 611-614
39. Goldman, D. L., S. C. Lee, and A. Casadevall: Tissue Localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63 (1995) 3448-3453
40. Gordon, M. A.: Synergistic serum therapy of systemic mycoses. Mycopathologia 19 (1963) 150
41. Gordon, M. A. and A. Casadevall: Serum therapy of cryptococcal meningitis. Clin. Infect. Dis. (in press) (1995)
42. Gordon, M. A. and E. Lapa: Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114 (1964) 373-378
43. Gordon, M. A. and D. K. Vedder: Serologic tests in diagnosis and prognosis of cryptococcosis. JAMA 197 (1966) 131-137
44. Goren, M. B.: Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J. Immunol. 98 (1967) 914-922
45. Goren, M. B. and G. M. Middlebrook: Protein conjugates of polysaccharide from Cryptocoecus neoformans. J. Immunol. 98 (1967) 901-913
46. Graybill, J. R. and J. Ahrens: Immunization and complement interaction in host defense against murine cryptococcosis. Journal of the Reticuloendothelial Society 30 (1981) 347-357
47. Graybill, J. R., M. Hague, and D. J. Drutz: Passive immunization in murine cryptococcosis. Sabouraudia 19 (1981) 237-244
48. Griffin, F. M.: Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptocoecus neoformans. Proc. Natl. Acad. Sci. 78 (1980) 3853-3857
49. Gupta, S., M. Ellis, T. Cesario, M. Ruhling, and B. Vayuvegula: Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T-cell function. Am. J. Med. 82 (1987) 129-131
50. Han, Y. and J. E. Cutler: Antibody response that protects against disseminated candidiasis. Infect. Immun. 63 (1995) 2714-2719
51. Henderson, D. K., J. E. Bennett, and M. A. Huber: Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J. Clin. Invest. 69 (1982) 1185-1190
52. Henderson, D. K., V. L. Kan, and J. E. Bennett: tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin. Exp. Immunol. 65 (1986) 639-646
53. + T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175 (1992) 1685-1695
54. Hirano, A., H. M. Zimmermann, and S. Leuine: Fine structure of cerebral fluid accumulation. VI Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria. Arch. Neurol. 12 (1965) 189-196
55. Hobbs, M. M., J. R. Perfect, D. L. Granger, and D. T. Durack: Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun. 58 (1990) 2115-2119
56. Houpt, D. C., G. S. T. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel: Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62 (1994) 3857-3864
57. Karaoui, R. M., N. K. Hall, and H. W. Larsh: Role of macrophages in immunity and pathogenesis of experimental cryptococcosis induced by the airborne route-Part II: Phagocytosis and intracellular fate of Cryptococcus neoformans. Mykosen 20 (1977) 409-422
58. Kirkham, P. M., F. Mortari, J. A. Newton, and H. W. Schroeder: Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J. 11 (1991) 603-609
59. Kligman, A. M.: Studies of the capsular substance of torula histolytica and the immunologic properties of torula cells. J. Immunol. 57 (1947) 395-401
60. Kozel, T. R.: Opsonization and phagocytosis of Cryptococcus neoformans. Arch. Med. Res. 24 (1993) 211-218
61. Kozel, T. R. and J. Jr. Cazin: Immune response to Cryptococcus neoformans soluble polysaccharide. Infect. Immun. 5 (1972) 35-41
62. Kozel, T. R. and E. Gotschlich: The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129 (1982) 1675-1680
63. Kozel, T. R., W. F. Gulley, and J. Jr. Cazin: Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18 (1977) 701-707
64. Kozel, T. R. and T. G. McGaw. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect. Immun. 25 (1979) 255-261
65. Kozel, T. R., G. S. T. Pfrommer, A. S. Guerlain, B. A. Highison, and G. J. Highison: Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev. Infect. Dis. 10 (1988) S436-S439
66. Kwon-Chung, K. J. and J. C. Rhodes: Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect. Immun. 51 (1986) 218-223
67. Kyong, C. U., G. Virella, H. H. Fudenherg, and C. P. Darby: X-linked immunodeficiency with increased IgM: clinical, ethnic, and immunologic heterogeneity. Pediatr. Res. 12 (1978) 1024-1026
68. La Mantia, L., A. Salmaggi, L. Tajoli, D. Cerrato, E. Lamperti, A. Nespolo, and G. Bussone: Cryptococcal meningoencephalitis: intrathecal immunological response. J. Neurol. 233 (1986) 362-366
69. Lane, H. C., H. Masur, L. Edgar, G. Whalen, A. H. Rook, and A. S. Fauci: Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. New. Engl. J. Med. 309 (1983) 453-458
70. Lee, S. L., Y. Kress, M.-L. Zhao, D. W. Dickson, and A. Casadevall: Cryptococcus neoformans survive and replicate in spacious phagosomes in human microglia. Lab. Invest. (in press) (1995)
71. Levitz, S. M.: Overview of host defenses in fungal infections. Clin. Infect. Dis. 14 (Suppl 1) (1992) S37-S42
72. Levitz, S. M., T. P. Farrell, and R. T. Maziarz: Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J. Infect. Dis. 163 (1991) 1108-1113
73. Lipscomb, M. F.: Lung defenses against opportunistic infections. Chest 96 (1989) 1393-1399
74. Littman, M. L.: Cryptococcosis (Torulosis). Am. J. Med. 27 (1959) 976-998
75. LoBuglio, A. F., R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, J. Ghrayeb, and M. B. Khazaeli: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. 86 (1989) 4220-4224
76. Louria, D. B. and T. Kaminski: Passively-acquired immunity in experimental cryptococcosis. Sabouradia 4 (1965) 80-84
77. Macher, A. M., J. E. Bennett, J. E. Gadek, and M. M. Frank: Complement depletion in cryptococcal sepsis. J. Immunol. 120 (1978) 1686-1690
78. Masur, H., F. P. Ognibene, R. Yarchoan, J. H. Shelhamer, B. F. Baird, W. Travis, A. F. Suffredini, L. Deyton, J. A. Kovacs, J. Falloon, R. Davey, M. Polis, et al.: CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 111 (1989) 223-231
79. Miller, M. F., T. G. Mitchell, W. J. Storkus, and J. R. Dawson: Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect. Immun. 58 (1990) 639-645
80. Mitchell, T. G. and J. R. Perfect: Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8 (1995) 515-548
81. Monga, D. P., R. Kumar, L. N. Mahapatra, and A. N. Malaviya: Experimental Cryptococcosis in normal and B-cell deficient mice. Infect. Immun. 26 (1979) 1-3
82. Moxon, E. R.: Haemophilus influenzae. In: Principles and practice of infectious diseases, edited by Mandell, G. L., Bennett, J. E. and Dolin, R. New York: Churchill Livingstone, 1995, p. 2039-2045
83. Mozaffarian, N., J. W. Berman, and A. Casadevall: Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774. 16 cells. J. Leukoc. Biol. 57 (1995) 657-662
84. Mukherjee, J., A. Casadevall, and M. D. Scharff: Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177 (1993) 1105-1106
85. Mukherjee, J., W. Cleare, and A. Casadevall: Monoclonal antibody mediated capsular reactions (quellung) in Cryptococcus neoformans. J. Immunol. Meth. 184 (1995) 139-143
86. Mukherjee, J., M. Feldmesser, M. D. Scharff, and A. Casadevall: Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemotherap. 39 (1995) 1398-1405
87. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall: Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181 (1995) 405-409
88. Mukherjee, J., L. Pirofski, M. D. Scharff, and A. Casadevall: Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. 90 (1993) 3636-3640
89. Mukherjee, J., M. D. Scharff, and A. Casadevall: Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60 (1992) 4534-4541
90. Mukherjee, J., M. D. Scharff, and A. Casadevall: Cryptococcus neoformans infection can elicit protective antibodies in mice. Can. J. Microbiol. 40 (1994) 888-892
91. Mukherjee, J., M. D. Scharff, and A. Casadevall: Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect. Immun. 63 (1995) 3353-3359
92. Mukherjee, J., L. Zuckier, M. D. Scharff, and A. Casadevall: Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrob. Agents Chemotherap. 38 (1994) 580-587
93. Mukherjee, S. and A. Casadevall: Monoclonal antibodies (MAbs) to Cryptococcus neoformans glucuronoxylomannan enhance macrophage antifungal activity. 34th International Conference of Antimicrobial Agents and Chemotherapy (Abstract) (1994) Orlando, FL.
94. Mukherjee, S., S. Lee, J. Mukherjee, M. D. Scharff, and A. Casadevall: Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62 (1994) 1079-1088
95. Mukherjee, S., S. C. Lee, and A. Casadevall: Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63 (1995) 573-579
96. Murphy, J. A.: Mechanisms of natural resistance to human pathogenic fungi. Annu. Rev. Microbiol. 45 (1991) 509-538
97. Murphy, J. W. and G. C. Cozad: Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5 (1972) 896-901
98. Musher, D. M.: Streptococcus pneumoniae. In: Principles and Practice of Infectious Diseases, edited by Mandell, G. L., Bennett, J. E. and Dolin, R. New York: Churchill Livingstone, 1995, p. 1811-1826
99. Nabavi, N. and J. W. Murphy: Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun. 51 (1986) 556-562
100. Nikolova, E. B. and M. W. Russell: Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8 stimulated cells. J. Leukoc. Biol. 57 (1995) 875-882
101. Otteson, E. W., W. H. Welch, and T. R. Kozel: Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J. Biol. Chem. 269 (1994) 1858-1864
102. Perfect, J. R., S. D. R. Lang, and D. T. Durack: Influence of agglutinating antibody in experimental cryptococcal meningitis. Br. J. Exp. Path 62 (1981) 595-599
103. Petito, C. K. and K. S. Cash: Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmorten brain. Ann. Neurol. 32 (1992) 658-666
104. Pettoello-Mantovani, M., A. Casadevall, and H. Goldstein: The presence of cryptococcal capsular polysaccharide increases the sensitivity of HIV-1 coculture in children. Ann. N.Y. Acad. Sci. 693 (1993) 281-283
105. Pettoello-Mantovani, M., A. Casadevall, T. R. Kollman, A. Rubinstein, and H. Goldstein: Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339 (1992) 21-23
106. Pettoello-Mantovani, M., A. Casadevall, P. Smarnworawong, and H. Goldstein: HIV-1 Infectivity is increased in vitro by the presence of the capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS and Human Retroviruses 10 (1994) 1079-1087
107. Pirofski, L., R. Lui, M. DeShaw, A. B. Kressel, and Z. Zhong: Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63 (1995) 3005-3014
108. Powderly, W. G.: Therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 14 (1992) 554-559
109. Rebers, P. A., S. A. Barker, M. Heidelberger, Z. Dische, and E. E. Evans: Precipitation of the specific polysaccharide of Cryptococcus neoformans A by types II and XIV antipneumococcal antisera. J. Am. Chem. Soc. 80 (1958) 1135-1137
110. Redd, S. C., G. W. Rutherford,III, M. A. Sande, A. R. Lifson, W. K. Hadley, R. R. Facklam, and J. S. Spika: The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J. Infect. Dis. 162 (1990) 1012-1017
111. Rhodes, J. C.: Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. J. Med. Vet. Mycol. 23 (1985) 225-234
112. Rhodes, J. C., L. S. Wicker, and W. Urba: Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29 (1980) 494-499
113. Sanford, J. E., D. M. Lupan, A. M. Schlagetter, and T. R. Kozel: Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58 (1990) 1919-1923
114. Sarosi, G. A., J. D. Parker, I. L. Dato, and F. E. Tosh: Amphotericin B in cryptococcal meningitis. Ann. Intern. Med. 71 (1992) 1079-1087
115. Savoy, A. C., A. M. Schlageter, L. C. Weinhold, D. M. Lupan, and T. R. Kozel: Acute toxicity after passive immunization in murine cryptococcosis. 95th ASM meeting, Washington, DC Abstract F-10 (1995)
116. Schackelford, P. G., S. J. Nelson, A. T. Palma, and M. H. Nahm: Human antibodies to group A streptococcal carbohydrate. J. Immunol. 140 (1988) 3200-3205
117. Schlagetter, A. M. and T. R. Kozel: Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58 (1990) 1914-1918
118. Schneerson-Porat, S., A. Sharar, and M. Aronson: Formation of histiocyte rings in response to Cryptococcus neoformans infection. Res. J. Reticuloendothe. Soc. 2 (1965) 249-255
119. Scott, E. N., H. G. Muchmore, and F. G. Felton: Enzyme-linked immunosorbent assays in murine cryptococcosis. Sabouradia 19 (1981) 257-265
120. Scott, M. G., D. Briles, P. G. Schackelford, S. Smith, and M. H. Nahm: Human antibodies to phosphocholine. IgG anti-PC antibodies express restricted numbers of V and C regions. J. Immunol. 138 (1987) 3325-3331
121. Shapiro, L. L. and J. B. Neal: Torula Meningitis. Arch. Neurol. Psychiat. 13 (1925) 174-190
122. Shari, A., M. Cosentino, S. F. Leitman-Klinman, and D. M. Klinman: Human immunodeficiency virus infection induces both polyclonal and virus specific B cell activation. J. Clin. Invest. 89 (1992) 561-566
123. Simberkoff, M. S., W. El Sadr, G. Schiffman, and J. J. Rahal: Streptococcus pneumoniae infections and bacteremia in patients with acquired immunodeficiency syndrome, with report of a pneumococcal vaccine failure. Am. Rev. Respir. Dis. 130 (1984) 1174-1176
124. Slack, J., G. P. Der-Balian, M. Nahm, and J. M. Davie: Subclass restriction of murine antibodies. II The IgG plaque-forming response to thymus-independent Type 1 and Type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J. Exp. Med. 151 (1980) 853-862
125. Spitzer, E. D., S. G. Spitzer, L. F. Freundlich, and A. Casadevall: Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 341 (1993) 595-596
126. Steinhoff, M. C., B. S. Auerbach, K. E. Nelson, D. Vlahov, R. L. Becher, N. M. H. Graham, D. H. Schwartz, A. H. Lucas and R. E. Chaisson: Antibody responses to Hemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. New Engl. J. Med 325 (1991) 1837
127. Sundstrom, J. B. and R. Cherniak: A glucuronoxylomannan of Cryptococcus neoformans serotype A is a Type 2 T-cell-independent antigen. Infect. Immun. 60 (1992) 4080-4087
128. Taber, K. W.: Torulosis in man. JAMA 108 (1937) 1405-1406
129. Tabone, M.-C., G. Leverger, J. Landman, C. Aznar, L. Boccon-Gibod, and G. Lasfargues: Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr. Infect. Dis. J. 13 (1994) 77-79
130. Toews, G. B., W. C. Vial, and E. J. Hansen: Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs. Infect. Immun. 50 (1985) 207-212
131. Williamson, P. R., J. E. Bennett, J. B. Robbins, and R. Schneerson: Vaccination for prevention of cryptococcosis. 2nd International Conference on Cryptococcus and Cryptococcosis (1993) Abstract L22-Page 60 (Abstract)
132. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff: Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol. 154 (1995) 1810-1816
133. Zebedee, S. L., R. K. Koduri, J. Mukherjee, S. Mukherjee, S. Lee, D. F. Sauer, M. D. Scharff, and A. Casadevall: Mouse-human immunoglobulin G1 chimeric antibodies with activity against Cryptococcus neoformans. Antimicrob. Agents Chemotherap. 38 (1994) 1507-1514
134. Zhong, Z., J. B. Robbins, R. Schneerson, and L. Pirofski: Phagocytosis of Cryptococcus neoformans by serum from recipients of cryptococcal polysaccharide vaccine. 95th ASM meeting, Washington, DC (Abstract) (1995)
135. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal: Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104 (1986) 234-240